Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Jennifer Chan, MD, MPH
Researchers at Dana-Farber Cancer Institute have uncovered a cancer
paradox: A family history of colon or rectal cancer doubles one's risk
of the disease — but improves the odds of survival should the cancer
A study appearing in the June 4 issue of the Journal of the American Medical Association
found that patients treated for stage III colorectal cancer fared
significantly better if they had a first-degree relative with the
disease than if they had no family history of colon or rectal cancer.
Having a family history conferred a 28 percent lower risk of a cancer
recurrence, being diagnosed with a new tumor, or dying from any cause
during the median 5.6-year follow-up.
The researchers do not fully understand the reason for the
paradoxical finding of increased risk but better prognosis in the
patients who had a family history of colorectal cancer. However they
noted there is precedent: A rare inherited condition called Lynch
syndrome strongly increases the risk of colorectal cancers that may
behave less aggressively than non-inherited "sporadic" cases of colon
In the new study, the more affected relatives a patient reported, the
better his or her odds became. Compared with participants without a
family history of colorectal cancer, participants with two or more
affected relatives had a 51 percent lower risk for cancer recurrence or
"This news may be reassuring to people with a family history, but our
hope is that we can discover what underlies this effect of family
history in biological terms," said Jennifer Chan, MD, MPH, of
Dana-Farber's Center for Gastrointestinal Oncology, first author of the
report. It is estimated that more than 153,000 cases of colon and
rectal cancer will be diagnosed in 2008, according to the American
Cancer Society, with more than 50,000 deaths.
An individual who has a first-degree relative with colorectal cancer
faces a doubled lifetime risk of being diagnosed with the disease —
approximately 2 in 20 odds, compared to 1 in 20 for those with no family
The findings emerged from a prospective study of 1,087 patients
enrolled in a randomized trial of two chemotherapy regimens following
surgery for stage III colon cancer. These cancers are characterized by
their deep penetration into the wall of the colon, or large intestine,
and have spread to nearby lymph nodes but not to other organs.
The patients were interviewed about family history of the disease and
some had DNA extracted from tumor samples. About 18 percent of the
patients reported a diagnosis of colon or rectal cancer in one or more
first-degree relatives. The patients were followed for an average of 5.6
years to measure their disease-free survival — the time from enrolling
in the study to being diagnosed with a recurrence of the tumor or a new
primary colon cancer, or death from any cause.
Examining just the risk for cancer recurrence, patients with a family
history of colorectal cancer had a 26 percent reduced risk compared
with patients without a family history. Cancer recurrence occurred in 27
percent of patients with a family history of colorectal cancer and 35
percent of patients without a family history. Patients with a family
history of colorectal cancer had a 25 percent reduction in risk of dying
from their cancer.
The scientists ruled out several explanations for the difference,
including the possibility that people with affected relatives adopted
healthier life styles or were diagnosed earlier. "We looked at important
lifestyle factors like diet, exercise and smoking, and found no
association. Since all patients had stage III cancers, earlier diagnosis
didn't explain it, either," explained Chan.
They also studied the potential effect of a kind of genetic
alteration seen in the tumors of patients with the inherited Lynch
syndrome that is associated with the elevated risk of colorectal cancer
in these families as well as their more-favorable prognosis. This
genetic change, known as microsatellite instability, did not appear to
explain the behavior of the more-common cancers associated with family
history in the new study.
Charles Fuchs, MD, of Dana-Farber, the senior author of the study,
said that the form of colorectal cancer associated with a family history
behaves differently because of "something biologic, but we just don't
know yet what that is."
In an effort to identify the biologic factor or factors, Fuchs and
his colleagues are examining hundreds of colorectal tumor samples for
common genetic changes. If some of these changes are found more often in
patients having a family history, it could lead researchers to
mechanisms in those cancers that explain their distinct behavior. In
turn, this understanding could help in devising better treatments.
"Meanwhile," said Fuchs, "the message is that people who have a
family history should be screened, and if they do get the cancer, they
appear to have a better outlook."
Screening — usually a colonoscopy — is recommended beginning at age
50 for people at average risk, and beginning at age 35 or 40 for those
with a family history.
Other authors include Jeffrey Meyerhardt, MD, MPH, and a number of
investigators from Dana-Farber and other institutions involved in the
treatment study that yielded data used in the analysis.
The treatment study, carried out by Cancer and Leukemia Group B, was
supported by grants from the National Cancer Institute and Pharmacia
& Upjohn Co., now Pfizer Oncology.
Dana-Farber Cancer Institute (www.dana-farber.org)
is a principal teaching affiliate of the Harvard Medical School and is
among the leading cancer research and care centers in the United States.
It is a founding member of the Dana-Farber/Harvard Cancer Center
(DF/HCC), designated a comprehensive cancer center by the National